Approval will expand access to the drug, which will be covered by Medicare under certain circumstances.
  • agentshags@sh.itjust.worksEnglish
    3·
    1 year ago

    Leqembi, from Japanese drugmaker Eisai and U.S.-based drugmaker Biogen, targets a type of protein in the brain called beta-amyloid, long thought by scientists to be one of the underlying causes of Alzheimer’s disease.